At the European Cancer Congress (ECC) 2015, Johan Vansteenkiste, MD, PhD, of KU Leuven, Leuven, Belgium, discusses the primary analyses of efficacy, safety and predictive biomarkers from POPLAR, a randomised phase 2 clinical trial of atezolizumab monotherapy versus docetaxel in patients with second- or third-line non-small cell lung cancer.
POPLAR: Phase 2 trial of atezolizumab monotherapy in non-small cell lung cancer
9th December 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now